CROs offering Phase III Clinical Trials with Biologics (Other)
28 published
28 published CROs match Phase III Clinical Trials and Biologics (Other).
Locations in this set include United States, United Kingdom, India, Australia, China, and Germany.
Capabilities that show up most often in this set: Phase II Clinical Trials, Phase IV / Post-Marketing, Phase I Clinical Trials, Data Management & eClinical, and Regulatory Affairs.
Matching companies
Simbec-OrionFull-service CRO delivering clinical trial management across early to late phases, with specialist expertise in rare diseases and oncology.
Syneos HealthGlobal CRO with 26,000+ employees offering integrated clinical development, regulatory affairs, and commercialization services. Helped develop or commercialize 96% of FDA-approved oncology drugs and 93% of EMA-authorized oncology products in the last five years.
Syngene InternationalInnovation-led CRDMO offering integrated scientific services from early discovery through commercial manufacturing, with cGMP-compliant facilities, 5,200+ scientists, and a new 50,000-liter single-use bioreactor capacity in the U.S.
TFS HealthScienceGlobal mid-size CRO specializing in dermatology, internal medicine, neuroscience, oncology, and ophthalmology with Phase I-IV clinical development, real-world evidence studies, and flexible resourcing solutions across 600+ experts in Europe, North America, and Australia.
TigermedLeading global CRO providing end-to-end clinical trial services, preclinical development, medical device and IVD trials, regulatory affairs, and real-world evidence studies across 180+ offices serving 4,000+ customers.
Veeda LifesciencesVeeda Lifesciences is a contract research organization offering preclinical R&D, BA/BE and bioanalytical studies, and Phase I–IV clinical trials for innovative, biosimilar, and generic drugs. Its capabilities cover both small and large molecules, including clinical bioanalysis and real-world evidence.
Velocity Clinical ResearchIntegrated clinical research site organization operating 60+ sites across the U.S. and Europe, supporting trials that contributed to 61 FDA-approved products since 1986.
WuXi AppTecGlobal CRDMO platform providing integrated end-to-end contract research, development, and manufacturing services across discovery, preclinical, clinical, and commercial phases for small molecules, peptides, oligonucleotides, and biologics across 30+ countries.
Markdown mirror: /explore/phase-3-clinical-trials/biologics-other.md